Go back

Inside out

Back page gossip from the 11 April issue of Research Europe

Competition overreach

An adviser to the EU’s top court has suggested that the European Commission overstepped the mark in blocking a move by the US-headquartered genomics sequencing giant Illumina to acquire Grail, a smaller US-based firm developing blood-based cancer tests.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.